Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,232 stopped studies mapped to B-Cell Malignant Neoplasm and descendants · 88% state a reason
Over the 1,232 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT03492268 | Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma | N/A | withdrawn | Apr 10, 2018 | Bioray Laboratories | Due to CART processing facility construction | Other (stated, no rule matched) |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | Phase 1 | terminated | Dec 7, 2012 | TG Therapeutics, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory… | Phase 2 | terminated | Aug 21, 2017 | University of Washington | Terminated due to loss of funding and former PI left the institution | Investigator |
| NCT04535102 | POLA+BR for Relapsed or Refractory DLBCL | Phase 2 | withdrawn | Sep 1, 2020 | University of Colorado, Denver | Lack of sufficient patient population | Other (stated, no rule matched) |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | Phase 2 | terminated | Oct 6, 2017 | University of Utah | Slow accrual | Enrollment / accrual |
| NCT05170789 | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma(ESdRRMM) | Phase 2 | withdrawn | Dec 28, 2021 | Tulane University School of Medicine | The study collaborator -Karyopharm- is not doing Myeloma studies funding, so they let the study… | Funding |
| NCT05183139 | A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and…(US MM-7) | Phase 4 | withdrawn | Jan 10, 2022 | Takeda | Business decision (no enrollment) | Enrollment / accrual |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab…(CITADEL-310) | Phase 3 | withdrawn | Apr 19, 2021 | Incyte Corporation | business decision; no enrolled patients | Enrollment / accrual |
| NCT04361851 | Study of Dara-Pembro for Multiple Myeloma Patients | Phase 2 | withdrawn | Apr 24, 2020 | Wake Forest University Health Sciences | Low enrollment due to competing studies | Enrollment / accrual |
| NCT04230031 | Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma | Phase 2 | withdrawn | Jan 18, 2020 | Wake Forest University Health Sciences | Difficult enrollment due to changes in standard of care | Enrollment / accrual |
| NCT03850522 | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | Phase 2 | terminated | Feb 21, 2019 | Lene Meldgaard Knudsen | Insufficient recruitment within planned enrolmentperiod. | Enrollment / accrual |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic… | Phase 2 | terminated | Nov 7, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT03312868 | Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma | Phase 2 | terminated | Oct 18, 2017 | Instituto do Cancer do Estado de São Paulo | Burocracy and funding | Funding |
| NCT04660045 | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Phase 2 | withdrawn | Dec 9, 2020 | Weill Medical College of Cornell University | Company supplying drug/funding ceased support. | Funding |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's… | Phase 1 / Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Per PI Request | Other (stated, no rule matched) |
| NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | Phase 2 | terminated | Apr 7, 2017 | Oncotherapeutics | The study was terminated early by Funding Sponsor due to low enrollment. | Enrollment / accrual |
| NCT04974996 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of…(LOTIS-8) | Phase 1 | withdrawn | Jul 23, 2021 | ADC Therapeutics S.A. | Decision to not proceed with study. | Other (stated, no rule matched) |
| NCT04115956 | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With… | Phase 1 | terminated | Oct 4, 2019 | Oncopeptides AB | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Sponsor / business decision |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 5, 2015 | Swiss Cancer Institute | SAKK Board decision of 14th November 2020 due to financial reasons. | Funding |
| NCT04990778 | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell… | Phase 2 | withdrawn | Aug 4, 2021 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | terminated | Dec 24, 2019 | National Heart, Lung, and Blood Institute (NHLBI) | Due to unexpected sudden death on study. | Other (stated, no rule matched) |
| NCT02998047 | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma | Phase 1 | terminated | Dec 20, 2016 | Actinium Pharmaceuticals | Poor recruitment | Enrollment / accrual |
| NCT01685606 | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight…(273) | Phase 2 | terminated | Sep 14, 2012 | Brown University | Lack of accrual and low efficacy | Efficacy / futility |
| NCT04448834 | Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | Phase 2 | withdrawn | Jun 26, 2020 | Dorothy Sipkins, MD, PhD | Study not moving forward | Other (stated, no rule matched) |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Jul 2, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT03880279 | Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma(TACTIC-19) | Phase 1 / Phase 2 | withdrawn | Mar 19, 2019 | Triumvira Immunologics, Inc. | Following a change in company governance, Triumvira terminated the study prior to enrolling any… | Enrollment / accrual |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | Phase 2 | terminated | Aug 5, 2019 | University of British Columbia | Slow enrolment, loss of funding | Enrollment / accrual |
| NCT04160195 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for… | Phase 1 | terminated | Nov 12, 2019 | National Cancer Institute (NCI) | The original principal investigator left the National Institutes of Health (NCI) and the decision… | Investigator |
| NCT04697290 | CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. | Early Phase 1 | suspended | Jan 6, 2021 | Beijing Tsinghua Chang Gung Hospital | Plan adjustment | Other (stated, no rule matched) |
| NCT00792506 | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | terminated | Nov 18, 2008 | Italfarmaco | The study was prematurely discontinued for lack of recruitement. | Enrollment / accrual |
| NCT03851081 | Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed… | Phase 1 / Phase 2 | withdrawn | Feb 22, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Genenta Science | Failure to recruit patients | Enrollment / accrual |
| NCT00792831 | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed… | Phase 2 | terminated | Nov 18, 2008 | Italfarmaco | Protocol needs complete restructuring in order to make it feasible and to complete the enrollment… | Enrollment / accrual |
| NCT04150692 | Escalation of Daratumumab Frequency Following Biochemical Progression in… | Phase 2 | withdrawn | Nov 5, 2019 | Washington University School of Medicine | Investigator decision | Investigator |
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | Phase 1 | terminated | Aug 29, 2019 | Klinikum Stuttgart | low recruitment | Enrollment / accrual |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | Phase 1 / Phase 2 | terminated | Sep 20, 2019 | AGC Biologics S.p.A. | Inability to close the study in a clinically relevant time frame | Other (stated, no rule matched) |
| NCT00384111 | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular… | Phase 3 | terminated | Oct 5, 2006 | Spectrum Pharmaceuticals, Inc | Study was terminated early as per the Sponsor's decision. | Sponsor / business decision |
| NCT02589860 | Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous… | — | withdrawn | Oct 28, 2015 | Sherif S. Farag | No accrual | Enrollment / accrual |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | Phase 1 | terminated | Nov 25, 2019 | The First Affiliated Hospital with Nanjing Medical University | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT03153514 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's…(CLLTX1) | Phase 2 | terminated | May 15, 2017 | German CLL Study Group | Prematurely terminated due to poor accrual | Enrollment / accrual |
| NCT01510184 | Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly… | Phase 3 | terminated | Jan 13, 2012 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen… | Phase 2 | terminated | May 17, 2019 | Jazz Pharmaceuticals | Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20… | Efficacy / futility |
| NCT03135262 | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants… | Phase 1 / Phase 2 | terminated | May 1, 2017 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. | Sponsor / business decision |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic… | Phase 1 | terminated | Jan 9, 2019 | AbbVie | Safety | Safety / toxicity |
| NCT04918511 | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed…(COAST) | Phase 1 | withdrawn | Jun 9, 2021 | Oncopeptides AB | Sponsor made the decision to terminate the COAST study to refocus the OPD5 clinical program. | Other (stated, no rule matched) |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | Phase 1 | withdrawn | Aug 21, 2018 | Virginia Commonwealth University | Slow Accrual | Enrollment / accrual |
| NCT03943342 | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After… | Phase 2 | withdrawn | May 9, 2019 | Kerry Rogers | Study not feasible | Other (stated, no rule matched) |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With… | Phase 2 | terminated | May 28, 2007 | Rush University Medical Center | Lack of accrual and interest in study | Enrollment / accrual |
| NCT03593109 | A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of… | Phase 1 | terminated | Jul 19, 2018 | Second Affiliated Hospital of Xi'an Jiaotong University | Suitable patients were not recruited | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated May 18, 2022source: clinicaltrials